Keywords: Biodel, Linjeta, Diabetes type 1 and 2, USA, FDA, Insulin

Biodel slumps as US FDA calls for more data on diabetes drug candidate Linjeta

Article | 02 November 2010

Print This

Shares of US specialty pharmaceutical firm Biodel (Nasdaq: BIOD) plunged 52% to $1.74 in early trading yesterday, after the US regulator said ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in